Health Policy
Richard G. Frank, PhD; Tricia Neuman, ScD
free access
JAMA. 2021;325(4):341-342. doi:10.1001/jama.2020.26026
This Viewpoint proposes policy options to forestall insolvency of the Medicare Hospital Insurance Trust Fund, including practical and politically palatable strategies to increase revenues and decrease spending to prevent looming shortfalls.
-
Editorial
Health Care Is a Right, Not a Privilege: A New Series on US Health Care and Health Policy
Howard Bauchner, MD; Phil B. Fontanarosa, MD, MBA; Karen Joynt Maddox, MD, MPH
-
Conversations with Dr Bauchner:
Health Care Reform in the Biden Era
Frederick P. Rivara, MD, MPH; Fredrick E. Vars, JD; Ali Rowhani-Rahbar, MD, MPH, PhD
free access
has audio
JAMA. 2021;325(4):343-344. doi:10.1001/jama.2020.24206
This Viewpoint reviews 3 policy options with broad political support that have been shown or are being studied to reduce gun violence: mapping sites for individuals to temporarily store their firearms during a crisis, voluntary do-not-sell lists, and extreme risk protection orders to restrict firearm purchase and possession by individuals at high risk of harm.
-
Conversations with Dr Bauchner:
Three Interventions to Address the US Pandemic of Firearm Injury and Death
-
Editorial
Firearm-Related Mortality: A Global Public Health Problem
Frederick P. Rivara, MD, MPH; David M. Studdert, LLB, ScD, MPH; Garen J. Wintemute, MD, MPH
Y. Tony Yang, ScD, LLM, MPH; Diana J. Mason, PhD, RN
free access
JAMA. 2021;325(4):345-346. doi:10.1001/jama.2020.24509
This Viewpoint explains how pharmaceutical companies use “nurse ambassadors,” paid registered nurses who interact with patients in home or phone visits to facilitate provision, administration, and refills of expensive medication, and implications of a 2020 settlement between AbbVie and the state of California requiring improved disclosures but largely allowing the programs to continue.
Matthew E. Hirschtritt, MD, MPH; Mark Olfson, MD, MPH; Kurt Kroenke, MD
free access
JAMA. 2021;325(4):347-348. doi:10.1001/jama.2020.22106
Following a September 2020 FDA announcement of a boxed warning for benzodiazepines, this Viewpoint reviews the relative benefits and risks of the drugs to reduce overuse in at-risk patients, moderate underuse in clinically appropriate instances, and guide judicious, rational prescribing.